A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

Summary

This is a phase II study to evaluate the safety, feasibility and efficacy of immunotherapy with GRNVAC1 in patients with AML.

Timeline

Start

2007-07

Primary completion

2011-12

Completion

2014-08

Outcome

Met primary endpoint

release “Last year we presented that the primary end-points for this study, safety and feasibility, were met.” geron.com ↗

Drugs

Indications